Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Reduces insurance approval delays for autoimmune and blood disorder treatments.
The problem
Insurance companies require prior authorization before approving certain medications, delaying treatment for patients with autoimmune and blood disorders. This process can harm health outcomes.
The proposal
Requires insurers to streamline prior authorization for autoimmune and blood disorder medications, setting faster approval timelines and limiting documentation requirements.
The impact
Patients with autoimmune and blood disorders gain faster access to prescribed treatments. Insurance companies face new operational requirements. Healthcare providers spend less time on approval paperwork.
Patients with serious autoimmune and blood disorders can start treatment sooner instead of waiting for insurance approval. This can prevent disease progression and improve health outcomes. Faster treatment may reduce emergency room visits.
Doctors and nurses spend less time on paperwork fighting with insurers. They can focus more time on patient care. This makes healthcare delivery more efficient.
Insurance companies get specific timelines and requirements instead of vague standards. This creates consistency across the industry and helps companies plan resources better.
Quick access to appropriate medications can prevent complications and hospitalizations. This improves quality of life for patients with these serious conditions.
Faster approvals may lead to more medications being covered, raising insurance expenses. Insurers may pass these costs to employers and patients through higher premiums.
Streamlined approval processes may reduce insurers' ability to catch unnecessary or inappropriate prescriptions. This could lead to overuse of expensive medications.
The bill only covers autoimmune and blood disorders, not other serious conditions. Patients with other diseases still face prior authorization delays.
Insurance companies need time and money to change their systems to meet new requirements. Small insurers may struggle more than large ones to comply.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.